Novo Nordisk Raises 2023 Sales Outlook on Strong Demand for Wegovy and Ozempic


Novo Nordisk has raised its full-year sales and operating profit outlook due to high demand for its weight loss drug Wegovy and diabetes treatment Ozempic. The company now expects 2023 sales growth of 32% to 38%, up from a previous forecast of 27% to 33%, driven by strong Ozempic sales in the U.S. and sales adjustments for Ozempic and Wegovy. Novo Nordisk's shares also reached a new 52-week high following the announcement.

Read more at CNBC >

Previous
Previous

Fatal Coal Train Derailment Shuts Down Interstate 25 in Southern Colorado

Next
Next

Geopolitical Conflict and 'Fragmentation': Impacts on Supply Chains and 'Slowbalisation